Bone Health Technologies

Bone Health Technologies develops and manufactures Osteoboost, an FDA-cleared, wearable vibration therapy device designed to treat osteopenia in postmenopausal women. The device uses targeted mechanical stimulation technology inspired by NASA research on bone loss mitigation in astronauts. Osteoboost is a drug-free, prescription-strength treatment worn as a belt that delivers localized vibrations to stimulate bone-building cells. In a 12-month clinical trial, the device demonstrated 85% reduction in vertebral bone density loss and 83% reduction in vertebral bone strength loss in women using it at least 3 times weekly, compared to placebo. The company received FDA clearance through the De Novo pathway as the first-of-its-kind treatment for osteopenia. The device showed no device-related serious adverse events in clinical trials and is HSA/FSA eligible. Osteoboost addresses a significant clinical gap in early-stage bone health intervention, filling the void between osteopenia diagnosis and pharmaceutical treatment. The company has secured $8M in recent funding to expand production and market access. The device is currently available for direct consumer purchase and requires a prescription from a healthcare provider. Manufacturing and clinical validation meet FDA standards for Class II medical devices.